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A b s t r a c t - - W e  have demonstrated recently that incubation of the aminoglycoside gentamicin with an 
hepatic post-mitochondrial fraction produces a compound toxic to sensory cells from the inner ear in 
short-term culture; in contrast, the parent aminoglycoside was non-toxic in vitro (Huang MY and 
Schacht J, Biochem Pharmacol40: Rll-R14, 1990). In the present study, we investigated the subcellular 
distribution of the enzymatic activity and the nature of the metabolite. Isolated outer hair cells from 
the guinea pig cochlea were used to assay for cytotoxicity. The enzyme(s) responsible for this novel 
reaction of aminoglycosides was exclusively localized to the cytosolic fraction of guinea pig liver. No 
activity was detected in nuclear, lysosomal/mitochondrial or microsomal preparations. Furthermore, 
the toxin-forming enzymatic activity was associated with the high molecular weight fraction of the 
cytosol and did not require low molecular weight components. Filtration of the toxin through molecular 
weight cut-off membranes showed a molecular size of approximately 500. This evidence is consistent 
with the toxin being a gentamicin derivative. 
Biotransformation of drugs by the liver, the major 
organ for xenobiotic metabolism, has been well 
established. The formation of reactive metabolites 
may indeed be the underlying mechanism of a variety 
of toxic drug actions. Aminoglycoside antibiotics 
(e.g. streptomycin, neomycin and gentamicin) are 
recovered from the body largely unchanged, and it 
has been assumed, therefore, that they do not 
undergo significant metabolism [1]. A radiotracer 
study [2] reported the presence of some non- 
gentamicin material in the urine of subjects receiving 
tritiated gentamicin but the relation to the injected 
material was unknown. While the acute and 
reversible actions of aminoglycosides may not require 
metabolism [3], the expression of irreversible 
cytotoxicity appears to be linked to a metabolite 
rather than the parent drug. Aminoglycosides which 
damage the kidney and the inner ear in vivo [4, 5] 
are not cytotoxic for isolated cochlear outer hair 
cells or renal cells in vitro [6, 7]. Earlier we presented 
evidence suggestive of a metabolic step involved in 
aminoglycoside toxicity [8] and more recently 
demonstrated the gentamicin-dependent formation 
of a cytotoxin [9] by a post-mitochondrial "$9" 
fraction [10] in vitro. 
An understanding of this novel reaction of 
aminoglycosides requires knowledge of the nature 
of the metabolite(s) and the enzyme(s) involved. 
Microsomal enzymes linked to cytochrome P450 are 
commonly associated with drug metabolism, but 
enzymes in other subcellular compartments will also 
modify xenobiotics. Some monooxygenase reactions 
are carried out by soluble enzymes [11] as 
are structural modifications such as acylation, 
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methylation, and sulfation, as well as conjugation 
reactions with glucuronide~ and glutathione [12]. 
Enzymes of amine metabolism which may be relevant 
for modification of aminoglycosides are also found 
in nuclear and mitochondrial fractions. 
In this study, we localized the enzyme(s) of 
gentamicin metabolism in subcellular fractions from 
guinea pig liver. In addition, we provide evidence 
that the toxin is a gentamicin derivative. The recently 
developed bioassay with isolated outer hair cells 
[6, 9] was employed to detect toxin formation. 
MATERIALS AND METHODS 
Subcellular fractionation. Liver from pigmented 
guinea pigs (200-250 g body weight) was minced and 
homogenized in 3 vol. of 250 mM sucrose and 20 mM 
sodium HEPES (N-[2-hydroxyethyl] piperazine-N'- 
[2-ethanesuifonic acid]), pH 7.4, in a teflon/glass 
homogenizer for 30 sec (two passes) with the pestle 
driven at approximately 1,000 rpm. The homogenate 
was filtered through gauze and centrifuged for 10 min 
at 1,500g to obtain a nuclear pellet and a post- 
nuclear supernatant. The latter was separated into 
a mitochondrial/lysosomal pellet and supernatant by 
centrifugation for 20rain at 12,000g. The post- 
mitochondrial supernatant was centrifuged for 1 hr 
at 100,000g to yield a microsomal pellet and 
the cytosol. Each pellet was washed gently in 
homogenizing buffer and centrifuged again at the 
appropriate speed. The washed pellets were 
then resuspended to the volume of the original 
homogenate. For some experiments, cytosolic 
fractions were desalted by gel exclusion chroma- 
tography over Sephadex G-25 (Pharmacia, Uppsala, 
Sweden). All operations were carried out at 0--4 ° , 
and fractions were stored in glass tubes at - 20  ° . 
Formation ofmetabolite. Aliquots of each fraction 
were incubated with (final concentrations) 100 mM 
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sodium phosphate buffer or 20 mM sodium HEPES, 
pH 7.4, 4 mM NADPH, 30 mM KCI, 7 mM MgCI2, 
and 10 mM gentamicin sulfate (Sigma, St. Louis, 
MO) for 1 hr at 37 °. Reactions were terminated 
without inactivating the toxin by heating the mixtures 
for 1.5 rain at 55 °. Protein was removed by cen- 
trifugation at 12,000g for 10rain, and the depro- 
teinated incubation mixture was filtered through 
0.2/zm filters (Acro LC13, Gelman Science, Ann 
Arbor, MI) and kept on ice for immediate toxicity 
assay or stored in glass tubes at -20  ° for no longer 
than 1 week. 
Cytotoxicity assay. Outer hair cells were isolated 
from the apical cochlear turns of pigmented guinea 
pigs by microdissection [13]. Yield of viable cells 
from the apex by far exceeds that from lower turns 
making apical cells the preferred substrates in studies 
of isolated outer hair cells. The cells were maintained 
at room temperature in Hanks' Balanced Salt 
Solution (HBSS) without phenol red or sodium 
bicarbonate, buffered with 5 mM sodium HEPES, 
pH 7.4, and adjusted to 300 +- 1 mOsM with NaC1. 
For cytotoxicity assays, the isolated cells were 
exposed for 60 min to the deproteinated incubation 
mixtures diluted 1:10 (v/v) in HBSS. Membrane 
integrity of cells was determined by exclusion of the 
nuclear dye propidium iodide (final concentration, 
1/~M); stained, enucleated, granular, or severely 
swollen cells were considered non-viable. 
Molecular size of metabolite. A molecular weight 
cut-off membrane (SpectraPor 100, 500, and 1000 
from Spectrum, Los Angeles, CA; 12,000 from 
Sigma) was placed in a centrifugal filter apparatus 
(Rainin, Woburn, MA). The deproteinated reaction 
mixture containing the toxic metabolite was first 
passed through a 0.2/~m syringe filter and then 
centrifuged at 19,200g for 1-2 hr. After centrifu- 
gation, the membranes were examined under a 
microscope to ensure that no tears or holes were 
present. The filtrates were then assayed for cytotoxic 
activity. 
Analysis and purification of gentamicin. Com- 
mercial gentamicin (gentamicin sulfate, Schering, 
Bloomfield, NJ) was analyzed by TLC. Samples 
were developed on HPTLC Silica Gel 60 (E. 
Merck, Gibbstown, NJ) in the lower phase 
of chloroform : methanol: 29% aqueous ammonia 
(1:1:1, by vol.) [14]. TLC tanks were equilibrated 
with the solvent for several hours before each run. 
After development, the plates were dried and then 
sprayed with a solution of fluorescamine (Sigma) in 
acetone (0.1 mg fluorescamine/mL acetone), and 
fluorescent bands were visualized under long-wave 
UV light. This analysis resolved the gentamicin 
components C1, C1, and C2 as major bands and at 
least six minor amine-reactive compounds. 
The major components C1, Cla and C2 of 
commercial gentamicin were purified on Silica Gel 
60 with a preadsorbent layer without fluorescence 
indicator (E. Merck). Five hundred microliters of 
an aqueous solution of 10 mg gentamicin sulfate/mL 
was spotted on the preadsorbent layer across the 
plate and allowed to dry. The developing solvent 
was the upper layer of chloroform: methanol: 29% 
aqueous ammonia (1 : 1 : 1, by vol.). After devel- 
opment, 1-cm wide vertical strips along each edge 
and in the middle of the plate were sprayed 
successively with 1% triethylamine (Pierce Chemical, 
Rockford, IL) in acetone, fluorescamine (as de- 
scribed above), and triethylamine, waiting several 
minutes between each spray. The major components 
of gentamicin, detected under long-wave UV light, 
migrated with an Rf > 0.7. After marking the position 
of gentamicin and removing the sprayed bands, the 
major gentamicin bands were scraped into a plastic 
centrifugation tube. Gentamicin was eluted by 
adding 5 mL of water, mixing repeatedly, and 
sedimenting the silica gel in a table-top centrifuge. 
The clear supernatant was removed, lyophilized, 
reconstituted into 300 #L of HBSS, and cleared from 
undissolved material through a prewashed 0.45 #m 
nylon centrifugal filter (Scientific Resources, Somer- 
set, NJ). Analytical TLC of this preparation showed 
the presence of gentamicin C1, Cla and C2 without 
contamination by amine-reactive compounds. 
RESULTS 
The "$9" fraction which we had used previously 
to metabolize gentamicin [9] is essentially a post- 
mitochondrial supematant. In preliminary experi- 
ments, a post-mitochondrial supernatant from guinea 
pig liver was further separated into a microsomal 
pellet and a cytosolic supernatant. The enzymatic 
activity that generated the cytotoxin in the presence 
of gentamicin remained with the cytosol, and little 
activity was found in the crude microsomes. The 
toxicity of the drug after incubation with the post- 
mitochondrial supernatant (3.6mg protein/mL 
incubation) or the cytosol (3.ling protein/mL 
incubation) was almost identical: percent viability of 
isolated outer hair cells was reduced to 24 +- 13 and 
25 +-9, respectively. Exposure of cells to control 
incubations without enzyme or without gentamicin 
consistently left 70-80% of the cells viable; this was 
similar to the viability of untreated cells immediately 
after isolation [6, 9]. 
Subsequently, toxin-generating enzymatic activity 
was quantified in all subcellular fractions (nuclei, 
mitochondria/lysosomes, microsomes, and cytosol) 
and compared to the activity in the total homogenate 
(Fig. 1). There was no significant formation of 
cytotoxin when gentamicin was incubated with the 
nuclear, mitochondrial/lysosomal, or microsomal 
fractions. Viability of hair cells remained between 
70 and 80% when they were exposed to gentamicin 
treated with these fractions. In contrast, the cytosol 
produced a toxic metabolite. The toxin-generating 
potency of the cytosol was quantitatively similar to 
that of the original homogenate, indicating that 
essentially all of the activity was recovered. Cell 
viabilities were reduced to 28 +-2% or 20 +--4% 
after exposure to gentamicin metabolized with 
homogenate or cytosol, respectively. 
Homogenate and cytosol contain both high and 
low molecular weight components. To assess a 
possible contribution of endogenous small com- 
pounds to gentamicin metabolism, low molecular 
size components were removed from the cytosol by 
chromatography over Sephadex G-25 (Table 1). The 
activity producing the cytotoxin was unaffected and 
remained associated with the high molecular size 
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Fig. 1. Subcellular distribution of gemtamicin-metabolizing 
enzyme activity. Gentamicin was metabolized with the 
subcellular fractions and cytotoxicity assayed as described 
in Materials and Methods. All fractions were added to the 
incubations in aliquots whose volume was identical to that 
of the homogenate. The final protein concentration per 
milliliter of incubation medium was 5.6 mg for homogenate, 
0.9mg for nuclei, 0.6rag for mitochondria/lysosomes, 
0.3 mg for microsomes, and 3.2 mg for cytosol. Percent 
viability is given as the mean - SD (N = 3). The activity 
in the homogenate and the cytosoi was significantly different 
from that in the other fractions at P < 0.001 (Student's t- 
test). 
eluate (>5 ,000Da) .  Similarly, exhaustive dialysis 
and t reatment  of cytosol with activated charcoal for 
the removal of low molecular  size compounds left 
the enzymatic activity essentially unchanged (data 
not shown). Toxin formation proceeded even in the 
absence of N A D P H ,  indicating that no exogenous 
cofactors were necessary for the reaction (Table 1). 
As observed before, omission of gentamicin or the 
cytosol from the incubations precluded generat ion 
of a toxin. 
In contrast to the enzymatic activity required for 
metabolism, the toxin itself exhibited an apparent  
molecular size of between 10 and 1,000 Da (Table 
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Table 2. Molecular size of the cytotoxic metabolite 
Molecular size Cells Viable cells 
of filtrate observed (% of total) 
Unfiltered cytosoi 350 26 
<12,000 184 27* 
< 1,000 356 37* 
<500 171 50t 
<100 240 76t 
Control: no cytosol 369 72 
Gentamicin was metabolized with a cytosolic fraction as 
described in Materials and Methods and the cytotoxin 
filtered through membranes with the permeation limits 
listed above. The results represent two to four independent 
experiments, and calculations of viability were based on 
the total number of cells observed. Statistical significance 
was determined by ANOVA of individual experiments. 
* Differs significantly (P < 0.05) from control but not 
from unfiltered cytosol. 
t Differs significantly (P < 0.05) from unfiltered cytosol 
but not from control. 
2). It passed through molecular size cut-off 
membranes  of 12,000 and 1,000 Da; these filtrates 
were as toxic as the unfiltered control. Filtrate 
through the 100 Da membrane  had lost its toxicity, 
indicating that the toxin was retained at this exclusion 
limit. The 500 Da fraction exhibited intermediate 
toxicity. 
Commercial  gentamicin consistently showed minor  
amine-reactive contaminants  upon chromatographic 
analysis in addition to the three major  isomers C1, 
Cla and C2. However,  gentamicin purified by thin- 
layer chromatography still produced a toxin (Table 
3) of apparently unchanged activity. 
DISCUSSION 
Drugs and xenobiotics are frequently metabolized 
Table 1. Association of gentamicin-metabolizing activity with the high molecular 
size fraction of cytosol 
Cells observed Viable cells* 
Fraction (total number) (% of total) 
Complete cytosol 399 35 
Desalted cytosoi 1192 37 
Desaited cytosol - NADPH 456 41 
Control: cytosol omitted 352 72 
Control: gentamicin omitted 212 68 
Gentamicin was metabolized and cytotoxicity assayed as described in Materials 
and Methods. The results represent combined data from three to seven assays 
per condition in three independent experiments. For each experiment, a desalted 
cytosol was prepared (protein concentration, 2.0 to 2.8mg/mL incubation 
medium) and compared to its corresponding complete cytosol (protein 
concentration, 1.8 to 2.8 mg/mL incubation medium). 
* Statistical significance was determined from individual experiments by a t- 
test: complete cytosol vs controls: P<0.01;  desalted cytosol vs controls: 
P < 0.01; complete vs desalted cytosol: not significant; desalted cytosol with vs 
without NADPH: not significant; and control without cytosol vs control without 
gentamicin: not significant. 
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Table 3. Formation of a cytotoxic metabolite from purified 
gentamicin 
Cells observed Viable cells 
Preparation (total number) (% of total) 
Commercial gentamicin 254 35 
Purified gentamicin 259 44 
Control: HBSS 166 75 
Gentamicin was purified and metabolized, and cyto- 
toxicity was assayed as described in Materials and Methods. 
The results represent combined data from two assays per 
preparation. 
in vivo by one of two general classes of reactions. 
One metabolic strategy generates a more polar 
metabolite from the parent compound, facilitating 
its renal excretion. These reactions are usually 
associated with microsomal cytochrome P450s, 
monamine oxidases and monooxygenases [12]. In 
contrast, reactions rendering a compound more 
hydrophobic, such as methylations, ethylations or 
acylations, are carried out by soluble enzymes [15]. 
Moreover, several enzymes of polyamine metabolism 
also are cytosolic. The latter are interesting 
candidates for an enzymatic conversion of amino- 
glycosides in view of structural and functional 
similarities between polyamines and amino- 
glycosides. 
Our results clearly indicate that the enzyme(s) of 
gentamicin metabolism is soluble. Throughout the 
subcellular fractionation, the enzymatic activity 
remained associated with the soluble fractions, and 
no loss of activity was observed. The fact that 
NADPH was not essential for the formation of the 
toxin is in contrast to our preliminary study [9] where 
a dependence on pyridine nucleotides suggested the 
involvement of P450-1inked enzymes. The conditions 
of the two studies are sufficiently different (use of 
a hepatic post-mitochondrial "$9" fraction from 
phenobarbital-treated animals vs a cytosolic fraction 
from untreated animals) to preclude direct com- 
parisons or to provide an explanation for the 
discrepancy. It now seems clear, however, that a 
cytosolic enzyme (or enzymes) without apparent 
cofactor requirement can account for the metabolism 
of gentamicin to a toxic metabolite. 
The identity of the metabolite remains speculative. 
Our original findings [9] could not rule oat a 
gentamicin-dependent formation of a cytotoxin from 
an endogenous precursor in the "$9" fraction. The 
present results suggest that the toxin is derived from 
gentamicin. The toxin has an apparent molecular 
size near 500 which corresponds well to that of the 
gentamicin complex (range'for gentamicins C1, Cla 
and C2:454 to 482). Moreover, the high molecular 
size fraction of the cytosol containing the toxin- 
forming enzymatic activity should be devoid of 
significant amounts of potential small endogenous 
precursors after Sephadex G-25 exclusion chroma- 
tography, exhaustive dialysis or treatment with 
activated charcoal. 
One final uncertainty about the nature of the toxin 
was raised by the presence of amine-reactive 
impurities in commercial gentamicin. The fact that 
purified gentamicin still produced a toxin apparently 
excludes the possibility that such contaminants rather 
than the major components Ca, Cla and C2 give rise 
to the cytotoxin. This notion is further supported 
by preliminary experiments showing the formation 
of toxic metabolites from other aminoglycosides, 
tobramycin and kanamycin [16]. 
An important question to be addressed is the 
relationship between our in vitro observations and 
the in vivo toxicity of aminoglycosides. Several 
potential extracellular and intracellular sites of drug 
action have been established [3]. The acute and 
reversible effects of aminoglycosides can be explained 
by the displacement of calcium ions from the plasma 
membrane and the block of voltage-gated calcium 
channels of outer hair cells [6]. This may be an 
action in addition to a block of transduction channels 
which has been shown to occur with streptomycin 
in the hair cells of the bullfrog saccule [17]. On 
the cytoplasmic side of the plasma membrane, 
phosphatidylinositol-4,5-bisphosphate acts as a 
"receptor" for aminoglycosides [3, 18]. Inhibition of 
phosphoinositide metabolism should interfere with 
the generation of second messengers from the lipid 
and thus with essential mechanisms of cell physi- 
ology. To what extent these actions of the native 
aminoglycosides contribute to the chronic toxicity 
remains to be established but none of these actions 
has been linked directly to irreversible damage to 
hair cells. Such irreversible damage may thus require 
the presence of the cytotoxic metabolite. This is 
consistent with observations that aminoglycosides 
can be detected in the inner ear and in hair cells 
long before physiological or structural damage is 
observed [19,20]. Thus, the formation of the 
metabolite or its accumulation to critical con- 
centrations appears to be a rate-limiting step in the 
toxic reaction sequence. 
The extent of metabolism of aminoglycosides in 
v i vo - -bo th  in terms of its rate and localization--is 
unknown. It is conceivable that the concentration of 
the metabolite is relatively low, making it a highly 
toxic species. This would explain why a toxic 
aminoglycoside metabolite has thus far escaped 
traditional methods of detection. Although the liver 
is capable of producing the metabolite, we cannot 
assume that this is the sole source or even one source 
of the metabolite for the destruction of kidney and 
inner ear. The liver is the major organ for drug 
metabolism in the body, but it is known that other 
tissues contribute to drug metabolism [21]. In fact, 
a local contribution to the development of organ- 
specific toxicity of aminoglycosides is suggested by 
reports that aminoglycosides applied directly into 
the fluids of the inner ear in vivo [22] or to otocyst 
whole organ cultures [23] produce toxic effects. The 
tissue distribution of drug-metabolizing enzymes is 
generally not uniform throughout the body [21] and 
several organs, including the inner ear, seem 
capable of aminoglycoside metabolism (unpublished 
observations). We therefore can postulate a higher 
endowment of the enzymes of aminoglycoside 
metabolism in renal and inner ear tissues to explain 
selective tissue damage. Similarly, a differential 
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distribution of these enzymes between the base and 
apex of the cochlea could explain the fact that the 
base is more sensitive to aminoglycosides than the 
apex. 
On the other hand, tissue sensitivity to amino- 
glycosides may reside in detoxification mechanisms 
rather than in the production of the cytotoxin alone. 
Liver which is not damaged by aminoglycosides is 
also a major organ for drug detoxification by 
mechanisms based on glucuronidation or conjugation 
with sulfhydryl compounds [12]. Toxic metabolites 
generated in the liver may be detoxified and only 
reach low steady-state concentrations. Glutathione- 
related pathways have been implicated in the 
detoxification of kanamycin [24,25], and the 
inactivation of the metabolite by sulfhydryl com- 
pounds and radical scavengers can be demonstrated 
in vitro [26]. Thus susceptibility may depend not 
only on the potential for forming the metabolite but 
also on the ability of tissues to inactivate it. 
The enzyme(s) and conditions of aminoglycoside 
metabolism now need to be further characterized. 
It may be that the metabolite is generated by a 
known enzymatic reaction hitherto not expected to 
use aminoglycosides as substrates. The finding of a 
previously undetected cytotoxic metabolite(s) of 
gentamicin offers a new approach to defining the 
mechanism of aminoglycoside toxicity, and to 
devising preventive strategies. 
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